Dyspepsia News and Research

RSS

Indigestion, known as ''upset stomach'' or ''dyspepsia'', meaning hard or difficult digestion, is a medical condition characterized by chronic or recurrent pain in the upper abdomen, upper abdominal fullness and feeling full earlier than expected when eating. It can be accompanied by bloating, belching, nausea, or heartburn.

Study shows global prevalence of functional gastrointestinal disorders

For every ten adults in the world, four suffer from functional gastrointestinal disorders of varying severity. This is shown by a study of more than 73,000 people in 33 countries. University of Gothenburg scientists are among those now presenting these results.

27 May 2020

Neuroscientists trace brain-to-gut pathways

Neuroscientists at the University of Pittsburgh Brain Institute have traced neural pathways that connect the brain to the stomach, providing a biological mechanism to explain how stress can foster ulcer development.

18 May 2020

Earbud-like nerve stimulator may offer relief for people suffering from indigestion

People who suffer frequent indigestion may find relief with a small device that hooks onto the ear known as a transcutaneous auricular vagus nerve stimulator, or taVNS. People who used taVNS showed significant improvements in their stomach's ability to accommodate and process a meal, according to a new study.

27 Apr 2020

AGA publishes clinical guideline for managing patients with gastric intestinal metaplasia

Gastric intestinal metaplasia (GIM), which is linked to non-cardia gastric cancer, is often detected during routine endoscopy, leading to questions about how patient care should be managed.

10 Dec 2019

Researchers develop revolutionary method using MRI to diagnose digestive disorder

A revolutionary method using MRI to diagnose a chronic digestive disorder has been developed by researchers at Nottingham Trent University.

30 Oct 2019

FDA approves new drug for specific type of highly treatment-resistant tuberculosis

The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis of the lungs.

14 Aug 2019

LYNPARZA Phase III SOLO-1 results show improved outcome for patients with advanced BRCA-mutated ovarian cancer

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

22 Oct 2018

World Stomach Day: International initiative to raise awareness and support for a vital organ

Tuesday, 2 October 2018 marks the first ever World Stomach Day, an international initiative to raise awareness and support for one of our most vital organs.

3 Oct 2018

PMDA approves use of LYNPARZA in patients with BRCA-mutated breast cancer

AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that Japan's Pharmaceuticals and Medical Devices Agency has approved LYNPARZA tablets for use in patients with unresectable or recurrent BRCA-mutated, human epidermal growth factor receptor 2 -negative breast cancer who have received prior chemotherapy.

2 Jul 2018

$Long-term PPI use not linked to increased hip fracture risk among Alzheimer's patients$

Long-term PPI use not linked to increased hip fracture risk among Alzheimer's patients

Long-term proton pump inhibitor (PPI) use does not increase the risk of hip fracture among persons with Alzheimer's disease, according to a new study from the University of Eastern Finland.

13 Mar 2018

FDA grants approval for first drug to treat inherited breast cancer

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation.

15 Jan 2018

U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer

AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LYNPARZA (olaparib) for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.

12 Jan 2018

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy).

17 Nov 2017

FDA approves first extended adjuvant therapy to lower risk of breast cancer recurrence

The U.S. Food and Drug Administration today approved Nerlynx (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer.

18 Jul 2017

Researchers find low adherence of physicians to H. pylori guidelines

It was long thought that gastric ulcers and other digestive woes were brought about by stress. But in 2005, clinical fellow Barry J. Marshall and pathologist J. Robin Warren were awarded the Nobel Prize in Physiology or Medicine for recognizing the role of Helicobacter pylori in gastritis and peptic ulcer disease.

15 Jun 2017

FDA approves new maintenance therapy for recurrent cancers

The U.S. Food and Drug Administration today approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy.

27 Mar 2017

Health psychologists now treating gastrointestinal disorders strongly affected by stress

Health psychologists have begun treating gastrointestinal disorders that are strongly affected by stress, including irritable bowel syndrome (IBS), Crohn's disease, functional heartburn, functional dyspepsia and ulcerative colitis.

25 Mar 2017

Rome IV criteria helps diagnose, treat gastrointestinal conditions in children

A child feels nauseated all the time, but no medical test can find what is wrong. Or a child vomits regularly, but there's no illness or eating disorder to explain it. These, and other stomach and bowel-related problems with no obvious causes, are called functional gastrointestinal disorders.

1 Jun 2016

Early-life stress may lead to functional dyspepsia in adulthood

Traumatic events early in life can increase levels of norepinephrine—the primary hormone responsible for preparing the body to react to stressful situations—in the gut, increasing the risk of developing chronic indigestion and anxiety during adulthood, a new study in American Journal of Physiology—Gastrointestinal and Liver Physiology reports.

27 May 2016

Cairn launches non-invasive Gastric Emptying Breath Test for measuring rate of gastroparesis in adults

Cairn Diagnostics, formerly known as Advanced Breath Diagnostics (ABDiagnostics), has launched the 13C-Spirulina Gastric Emptying Breath Test (GEBT).

30 Mar 2016